The 165-901 study is designed to identify the appropriate tools for use in future interventional studies on the neurocognitive effects of pegvaliase on adults with PKU.
Clinical studies have suggested that treatment with pegvaliase results in lowering of blood Phenylalanine levels in adults with Phenylketonuria (PKU). Because these individuals often exhibit inattention and mood difficulties, and blood Phe concentration affects cognition and mood, life-long blood Phe control with pegvaliase may improve cognitive abilities and emotional and mental health in patients with PKU. In order to adequately quantify potential pegvaliase treatment impact on cognition and mood, it is necessary to employ clinical outcome assessments (COAs) that are fit for purpose and that comprehensively address concepts important, relevant, and meaningful to PKU patients. This is an observational study to identify symptom, function, and health-related quality of life (HRQoL) concepts of interest (COIs) to patients with PKU and to seek additional patient, observer, and expert input on the appropriateness of concepts of BioMarin's proposed COAs for use in future efficacy trials in PKU.
Patients eligible to participate in this study must meet all of the following criteria:
≥18 and ≤70 years of age at the time of consent;
Clinically-confirmed diagnosis of Phenylketonuria (PKU);
Blood Phe test completed within eight weeks prior to screening date or blood Phe test completed within eight weeks post screening date;
Able to read, understand, and speak fluently the language(s) of their designated country sufficiently to participate in an interview and/or complete all assessments;
Willing and able to participate in a telephone interview lasting approximately 90 minutes;
Willing to be audio-recorded during the interview session;
Willing and able to provide written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate.
Patients meeting any of the following criteria will not be included in the study:
Current or previous exposure to pegvaliase treatment or participation in a pegvaliase clinical trial;
Has a significant cognitive impairment, hearing difficulty, visual impairment, acute psychopathology, medical condition, or insufficient knowledge of the interview language that, in the opinion of the investigator or interviewer, would interfere with his or her ability to provide written consent and participate/complete an interview.
January 14, 2020
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
For more information and to contact the study team: